Six-month results of the MASTER trial presented at EuroPCR

54

InspireMD, the leader in embolic protection stents, recently announced thier schedule of educational events and data presentations at EuroPCR 2013 in Paris, France (21–24 May), culminating in the first presentation of 6-month results from the MASTER (MGuard for Acute STE levation Reperfusion) trial of the MGaurd EPS.

Gregg W Stone, the MASTER study chairman and the director of the Cardiovascular Research and Education Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, USA, said:”In these STEMI patients, embolic protection is an unmet need that is not addressed by current bare metal or drug-eluting coronary stents. This year’s EuroPCR meeting will add important new data underlining the protective benefits of MGuard six months post-procedure.”

 

MGuard EPS is CE mark approved. It is not approved for sale in the US by the Food and Drug Administration at this time.

 

There will be an Inspire MD STEMI Symposium at EuroPCR on Thursday 23 May 2013 at 12:00, Room 242AB.